Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
-
New Four-Drug attack on deadly pancreatic cancer enters human testing
Disease control OngoingThis study is testing a new combination of four drugs for people with metastatic pancreatic cancer who have not yet received any treatment. The main goals are to find the safest and most effective dose of the new drug pair (avutometinib and defactinib) when added to two standard …
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat lung cancer: testing a powerful drug cocktail
Disease control OngoingThis study is testing a new combination of two or three drugs for people with a specific type of lung cancer (KRAS G12C Non-Small Cell Lung Cancer). It aims to see if the combination is safe and effective, especially for patients whose cancer has progressed after previous treatme…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New drug duo targets Tough-to-Treat ovarian cancer
Disease control OngoingThis study is testing the safety and effectiveness of two oral drugs, avutometinib and defactinib, given together to Japanese patients with a specific type of recurrent ovarian cancer. The goal is to see if this combination can shrink tumors and control the cancer in patients who…
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Feb 20, 2026 14:36 UTC